// App-Quantinova.ai

94 : LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.

Researchers

Presenter

  • Carlos Gomez-Roca

Principal Investigators

  • Eduardo Yanez

  • Seock-Ah Im

  • Eduardo Castanon Alvarez

  • Helene Senellart

  • Mark Doherty

  • Javier Garca-Corbacho

  • Juanita Suzanne Lopez

  • Bristi Basu

  • Corinne Maurice-Dror

  • Sanjeev Singh Gill

  • Razi Ghori

  • Peter Kubiak

  • Fan Jin

  • Kevin Glen Norwood

  • Hyun Cheol Chung

Medical Centers

  • Institut Claudius Regaud, Toulouse, France

  • Hematology-Oncology Unit, Department of Internal Medicine, School of Medicine,Universidad de la Frontera,Temuco,Chili

  • Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Institut de Cancerologie de l'Ouestsite Rene Gauducheau, Saint Herblain, France

  • Sunnybrook Health Sciences Center and University of Toronto, Toronto, Canada

  • Hospital Clinic de Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumours Lab (IDIBAPS), Barcelona, Spain

  • Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, United Kingdom

  • Department of Oncology, University of Cambridge, Cambridge, United Kingdom

  • The Rappaport Faculty of Medicine, Technion, Haifa, Israel

  • The Alfred Hospital, Melbourne, Australia

  • Merck & Co., Inc., Kenilworth, NJ

  • Eisai Inc, Woodcliff Lake, NJ

  • Yonsei Cancer Center, Yonsei University College of Medicine, Seoul,...

Locations

  • France

  • Chile

  • Republic of South Korea

  • Spain

  • Canada

  • United Kingdom

  • Israel

  • Australia

  • United States

Companies

  • Merck & Co., Inc.

  • Eisai Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

  • Microsatellite instability-high

Drug/Treatment

  • Pembrolizumab

  • Oxaliplatin

  • Irinotecan

  • Lenvatinib

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Open Label

  • Cohort

Phase

  • II

Study Id's

  • NCT03797326

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved